Reclast (Zoledronic Acid) Pregnancy and Lactation Safety

How Zoledronic Acid Works and Why Bone Retention Matters

Zoledronic acid is a nitrogen-containing bisphosphonate that binds with high affinity to hydroxyapatite in bone, where it inhibits farnesyl pyrophosphate synthase in osteoclasts and blocks bone resorption. A single 5 mg IV infusion of Reclast reduced new vertebral fractures by 70% over three years in the HORIZON-PFT trial (N=7,765) [1]. That potency comes from an unusually tight grip on the skeleton.

Once incorporated into bone matrix, zoledronic acid is released only when osteoclasts resorb the surrounding tissue. The terminal elimination half-life from bone exceeds 10 years [2]. This pharmacokinetic feature separates bisphosphonates from nearly every other drug class in reproductive safety discussions: stopping the medication does not clear it from the body. Small quantities continue to re-enter the maternal circulation during normal bone turnover, and that turnover accelerates during pregnancy when fetal calcium demand rises sharply in the third trimester [3].

For a drug given once a year, the question is not simply "was the patient taking it when she conceived?" The question is whether residual drug stored in maternal bone can cross the placenta in amounts sufficient to affect the fetus. Animal models suggest it can.

FDA Labeling and Regulatory Position

The Reclast prescribing information states plainly that zoledronic acid "can cause fetal harm when administered to a pregnant woman" and is contraindicated in pregnancy [4]. Under the Pregnancy and Lactation Labeling Rule (PLLR) format that replaced the old letter categories in 2015, the label includes a fetal risk summary, clinical considerations, and animal data rather than a single-letter grade.

The label requires a pregnancy test before each infusion in women of reproductive potential. It also recommends advising patients about the risk to the fetus and the need for effective contraception [4]. The FDA's language is direct. The 2018 label revision states: "There are no adequate and well-controlled studies of Reclast in pregnant women. Women of childbearing potential should be advised to use effective contraception" [4].

No specific washout period before attempting conception appears in the label. That gap creates clinical uncertainty, because the drug's bone half-life far outlasts the dosing interval.

Animal Reproductive Toxicity Data

Rat studies form the backbone of the reproductive safety profile. In pre- and postnatal development studies, zoledronic acid administered subcutaneously to pregnant rats at doses of 0.2 mg/kg/day (roughly equivalent to the systemic exposure from a human 5 mg IV dose on an AUC basis) caused increased pre-implantation and post-implantation losses, decreased fetal viability, and skeletal malformations including shortened, misshapen, or absent bones [4]. Dystocia was observed at all doses, linked to drug-induced hypocalcemia in the dams [4].

Rabbit studies showed no teratogenic effects at subcutaneous doses up to 0.1 mg/kg/day, but maternal toxicity limited dose escalation [4]. The rat findings carry more weight in clinical decision-making because the doses that produced harm were at or below human-equivalent exposures.

One consistent finding across bisphosphonate animal models is disruption of endochondral ossification in the fetal skeleton. The mechanism is predictable: bisphosphonates suppress osteoclast-mediated remodeling, and fetal bone development depends on tightly coordinated cycles of formation and resorption [5]. Blocking that cycle during organogenesis produces the skeletal anomalies seen in the rat data.

Human Pregnancy Exposure Data

No randomized trials have studied bisphosphonate use in pregnant women. The evidence comes from case reports, small case series, and retrospective reviews.

A 2008 systematic review by Djokanovic et al. identified 51 cases of bisphosphonate exposure during pregnancy across all agents (alendronate, pamidronate, etidronate, risedronate, and zoledronic acid). Of those, 78% resulted in live births without congenital malformations. Transient neonatal hypocalcemia occurred in several cases, and one case of a minor skeletal anomaly (a shortened femur that normalized postnatally) was reported [6]. The authors concluded that the human data, while limited, did not show the consistent pattern of major malformations predicted by rat studies.

A separate case series by Stathopoulos et al. reviewed outcomes in women who received IV bisphosphonates (including zoledronic acid) before pregnancy and found no major congenital anomalies among 12 exposed pregnancies [7]. Neonatal calcium levels were low-normal in several cases.

These findings are cautiously reassuring for women who become pregnant after prior bisphosphonate exposure. They do not, however, support intentional use during pregnancy. The sample sizes are too small to detect rare outcomes. Dr. Adi Ornoy of Hebrew University wrote in a 2006 review: "The available human data do not demonstrate a clear teratogenic risk, but the number of exposed pregnancies is far too small to rule out an increased risk of specific malformations" [8].

The distinction between active dosing during pregnancy and residual bone-stored drug from prior treatment is clinically meaningful. Most reported human exposures involved drug administered before conception, not during pregnancy. The clinical question facing most patients is exposure from bone stores, not from a recent infusion.

Preconception Planning After Zoledronic Acid

No professional society has issued a specific, evidence-based recommendation for how long to wait between the last zoledronic acid infusion and attempting conception. The Endocrine Society's 2019 Clinical Practice Guideline on postmenopausal osteoporosis does not address preconception timing for bisphosphonates, as the target population is postmenopausal [9]. The American College of Obstetricians and Gynecologists (ACOG) advises against bisphosphonate use in pregnancy but does not specify a washout interval [10].

In practice, many clinicians advise a minimum of 12 months between the last zoledronic acid infusion and conception attempts. This recommendation is based on expert opinion and the drug's pharmacokinetics, not on trial data. Some specialists suggest longer intervals of 18 to 24 months for women who received multiple annual infusions, reasoning that cumulative bone stores are higher.

The Endocrine Society guideline notes: "In women of childbearing potential, bisphosphonates should be used with caution and only when the benefit clearly outweighs the risk" [9]. For premenopausal women who require anti-resorptive therapy (such as those with glucocorticoid-induced osteoporosis or osteogenesis imperfecta), denosumab is sometimes considered as an alternative because it does not incorporate into bone matrix. Denosumab has its own reproductive concerns, but its effects reverse within approximately six months of discontinuation, offering a more predictable timeline for preconception planning [11].

A practical preconception checklist includes:

• Confirm the date and cumulative number of prior zoledronic acid infusions
• Obtain a baseline serum calcium and 25-hydroxyvitamin D level
• Ensure vitamin D repletion (target 30 to 50 ng/mL) and adequate calcium intake (1 to 000 mg/day) before conception
• Monitor serum calcium during pregnancy, particularly in the third trimester
• Plan for neonatal calcium screening in the first 48 hours after delivery

Lactation: What the Evidence Shows

The Reclast label states that it is not known whether zoledronic acid is excreted in human breast milk [4]. No published studies have measured drug concentrations in breast milk after IV zoledronic acid administration.

Bisphosphonates as a class are poorly absorbed from the gastrointestinal tract (oral bioavailability of alendronate is approximately 0.6%), which has led some pharmacologists to argue that even if small quantities appeared in breast milk, the infant's systemic absorption would be negligible [12]. This reasoning applies most directly to oral bisphosphonates. Zoledronic acid is given intravenously, bypassing the absorption question for the mother, but the infant would still need to absorb any drug present in milk orally.

The LactMed database, maintained by the National Library of Medicine, states that "because of the low oral bioavailability of bisphosphonates, the amount of drug in the infant's bloodstream is expected to be very small" but recommends caution given the lack of direct evidence [13]. No cases of adverse effects in breastfed infants exposed to maternal zoledronic acid have been published.

Given the once-yearly dosing schedule of Reclast, a practical approach is to defer the infusion until after weaning. If treatment cannot be delayed, some clinicians recommend a brief interruption of breastfeeding (24 to 48 hours after infusion) to reduce peak exposure, though no data confirm this strategy's effectiveness.

Fertility and Ovarian Function

Zoledronic acid does not appear to affect ovarian function directly. Animal fertility studies in female rats showed no impairment of mating or fertility at subcutaneous doses up to 0.1 mg/kg/day, though higher doses reduced fertility secondary to maternal toxicity and hypocalcemia [4].

In clinical practice, no published reports link zoledronic acid to impaired ovulation, reduced oocyte quality, or diminished ovarian reserve. The drug's target tissue is bone, not the reproductive axis. Women receiving zoledronic acid for conditions like Paget's disease or glucocorticoid-induced osteoporosis have conceived successfully after treatment, as documented in the case series discussed above [6][7].

Male fertility data are limited. Rat studies showed no effects on spermatogenesis at clinical-equivalent doses [4]. No human male fertility concerns have been reported.

When Zoledronic Acid Is Used in Premenopausal Women

Most Reclast prescriptions are written for postmenopausal women, where pregnancy is not a concern. Premenopausal use is less common but occurs in specific clinical scenarios: glucocorticoid-induced osteoporosis, osteogenesis imperfecta, cancer treatment-related bone loss, and anorexia nervosa with severe bone mineral density (BMD) reduction.

In these populations, the prescribing clinician must weigh the fracture reduction benefit against the reproductive implications. The HORIZON-PFT data showed a 70% reduction in morphometric vertebral fractures (3.3% vs. 10.9%, P<0.001) and a 41% reduction in hip fractures over three years [1]. For a premenopausal woman with T-scores below -2.5 and active fractures, those numbers may justify treatment even with reproductive counseling.

The American Association of Clinical Endocrinology (AACE) 2020 guideline recommends that premenopausal women receiving bisphosphonates "should be counseled about potential fetal risks and the long skeletal half-life of these agents" and should use reliable contraception throughout treatment [14].

Comparing Reproductive Risk Across Bisphosphonates

All bisphosphonates share the same bone-binding property and carry similar reproductive warnings. Zoledronic acid has the longest apparent bone half-life within the class due to its high binding affinity (binding constant approximately 100-fold greater than etidronate) [2]. Alendronate and risedronate have shorter but still multi-year bone retention times.

The clinical implication: switching from zoledronic acid to an oral bisphosphonate does not meaningfully reduce reproductive risk. If the goal is to minimize fetal exposure from stored drug, the entire bisphosphonate class presents the same fundamental challenge. For women actively planning pregnancy within one to two years, non-bisphosphonate options (denosumab with a planned washout, teriparatide, or romosozumab with its 12-month treatment course) may offer more predictable timelines [11].

Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic agents that do not bind to bone matrix. They are cleared from the body within hours of the last injection. Both carry a black-box warning based on osteosarcoma risk in rats, but neither raises the bone-storage concern relevant to pregnancy planning [15].

Monitoring a Pregnancy After Bisphosphonate Exposure

If a woman becomes pregnant after prior zoledronic acid treatment, standard obstetric care applies with a few additions. Serial ultrasound monitoring of fetal long-bone length in the second and third trimesters can detect the skeletal shortening seen in animal models. Maternal serum calcium should be checked at least once per trimester, with closer monitoring in the third trimester when fetal calcium demand peaks at approximately 250 to 300 mg per day [3].

After delivery, neonatal serum calcium and ionized calcium should be measured within the first 24 to 48 hours. Transient hypocalcemia, if present, typically responds to calcium supplementation and resolves within days [6].

No data support elective termination based solely on prior bisphosphonate exposure. The available human evidence, while limited, does not demonstrate a pattern of major congenital anomalies [6][7][8].